North America ADHD Therapeutics Market

North America ADHD Therapeutics Market Size (2024 to 2032)

The size of the North American attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to be worth USD 7.29 billion by 2032 from USD 4.18 billion in 2024, growing at a CAGR of 7.2% during the forecast period.

ADHD is becoming more common due to the lack of therapy, which is driving the market for attention deficit hyperactivity disorder therapies. In addition, the ADHD treatment market is being driven by the harsh effects of unstable lifestyles and preservatives in children's meals, increasing the occurrence of ADHD in the 4–7-year-old age group. 

Rising awareness of the syndrome among physicians and patients and a lack of routine diagnostic tests are expected to drive the North American ADHD market growth during the forecast period. In addition, other factors such as the rising medical developments, a growing number of neuroscience research projects, and increased public awareness about mental illness are expected to boost the market’s growth rate. 

On the other hand, the expansion of biotechnology and pharmaceutical companies’ focus on creating innovative therapies for ADHD is driving the market growth in the North American region. Furthermore, the adoption of cutting-edge technology in healthcare facilities, increasing healthcare spending, and rising disposable income are expected to propel the ADHD therapeutics market ahead in this region.  In addition, the medical sector's focus on improving infrastructure, the rising prevalence of various health diseases, and the expanding number of elderly populations are expected to showcase a significant positive impact on the market’s growth rate during the forecast period.

However, strict government laws governing the approval of medicines associated with neurosciences and the acceptable cost of ADHD medication are limiting the market expansion in North America. Another issue that limits growth is the use of ADHD medications, which are rarely used.

This research report on the North American ADHD therapeutics market has been segmented and sub-segmented into the following categories.

North America ADHD Therapeutics Market - By Medication

• Stimulants

• Non-Stimulants

North America ADHD Therapeutics Market - By Psychotherapy

• Behaviour Therapy

• Cognitive Behavioural Therapy

• Interpersonal Psychotherapy

• Family Therapy

North America ADHD Therapeutics Market - By Education or Training

• Parent Management Training

• Social Skills Training

• School-Based Interventions

North America ADHD Therapeutics Market - By Country

• The United States

• Canada

• Rest of North America

Geographically, the North American regional market held the largest share of the worldwide ADHD therapeutics market in 2023, accounting for around 36% due to a well-developed economy, early adoption of sophisticated technology, and high per capita healthcare costs. In addition, the presence of established companies in the region and due to the introduction of products by regional players during the forecast period, for example, Adlon Therapeutics L.P., a Purdue Pharma L.P. company, gained FDA clearance in March 2019 for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII for the treatment of attention deficit hyperactivity disorder in patients aged six years and older.

The U.S. ADHD therapeutics market dominated the North American market, and it is anticipated to register a predominant share during the forecast period. The growing number of patients with attention deficit hyperactivity disorder (ADHD) and high healthcare costs drive the market growth. Also, the availability of advanced healthcare infrastructure, increasing healthcare spending, and favorable reimbursement policies fuel market growth. 

KEY MARKET PLAYERS

A few of the prominent companies operating in the North American attention deficit hyperactivity disorder (ADHD) therapeutics market are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).